Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Asia

Asia

In Asia, the revenue in the Other Vaccines market is projected to reach €9.94bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 10.99%, resulting in a market volume of €16.74bn by 2029.
When compared globally, United States is expected to generate the highest revenue, with €22,940.00m in 2024.
In Asia, the demand for other vaccines is rapidly increasing, with countries like Japan and South Korea investing heavily in research and development for new and improved immunization solutions.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Other Vaccines market in Asia has been growing steadily in recent years due to various factors.

Customer preferences: Customers in Asia are becoming more health-conscious and are increasingly aware of the importance of vaccination. They are willing to invest in preventive healthcare measures to avoid the high costs of treatment for illnesses. This has led to an increase in demand for vaccines, including Other Vaccines.

Trends in the market: In China, the Other Vaccines market has been growing rapidly due to the government's efforts to improve healthcare access and coverage. The government has also implemented policies to encourage the development of domestic vaccine manufacturers, which has led to increased competition and innovation in the market.In India, the Other Vaccines market has been driven by the increasing incidence of infectious diseases and the government's focus on immunization programs. The government has launched various initiatives to increase vaccination coverage, which has led to an increase in demand for vaccines.In Japan, the Other Vaccines market has been growing due to the aging population and the high prevalence of chronic diseases. The government has also implemented policies to encourage the development of new vaccines and improve vaccination coverage.

Local special circumstances: In some countries in Asia, there have been concerns about the safety and efficacy of vaccines, which has led to vaccine hesitancy among some customers. This has been a challenge for vaccine manufacturers and healthcare providers, who have had to work to address these concerns and improve public trust in vaccines.

Underlying macroeconomic factors: The growing middle class in Asia has led to an increase in demand for healthcare services, including vaccines. Economic growth and rising incomes have also led to increased government spending on healthcare and public health initiatives, which has further driven the growth of the Other Vaccines market. Additionally, the COVID-19 pandemic has increased awareness of the importance of vaccines and has led to increased investment in vaccine development and production.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.